THIS WEEK
September 28, 2000
in the New England Journal of Medicine

 


Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Irinotecan is active against metastatic colorectal cancer and interferes with an enzyme (topoisomerase I) that is critical for DNA replication. This study of almost 700 patients compared the standard therapy for metastatic colorectal cancer, fluorouracil plus leucovorin, with a combination of irinotecan plus these two agents. A third group received irinotecan alone. As compared with the other treatments, the triple-drug combination yielded moderate, statistically significant improvements in progression-free survival and the tumor-response rate.

Multiple Complex Coronary Plaques in Patients with Acute Myocardial Infarction
Acute myocardial infarction is believed to result from the rupture of a single unstable coronary plaque; however, the development of unstable plaques may be a widespread process. In this study, two fifths of the 253 patients with acute myocardial infarction had angiographic evidence of multiple complex coronary plaques, which are at risk for becoming unstable. As compared with patients with only one complex plaque, those with multiple complex plaques had a higher risk of recurrent acute coronary syndromes and a greater need for repeated angioplasty or for coronary bypass surgery during the following year.

Effect of Growth Hormone in Children with Chronic Renal Failure
Children with chronic renal insufficiency have poor growth, and their short-term growth improves in response to growth hormone therapy. Whether treatment increases their adult height is not known, however. In 38 such children, who were treated with growth hormone for an average of 5.3 years starting at an average age of 10.4 years, the mean final height was increased by 1.4 SD over their standardized height at the start of treatment, and the majority of children achieved adult height within the normal range.

Liver Involvement in Hereditary Hemorrhagic Telangiectasia
photographPatients with hereditary hemorrhagic telangiectasia have angiodysplastic lesions that affect many organs. This study examined the types of liver involvement in 19 patients with this disease. There were three distinct presentations: high-output heart failure, portal hypertension, and biliary disease.

Interferon Beta-1a Treatment for a First Demyelinating Event

Interferon beta is known to have benefits in the treatment of patients with established multiple sclerosis, but it is not known whether treatment of patients earlier in the course of this disease is of benefit. In this trial, 383 patients with a first attack of optic neuritis, incomplete transverse myelitis, or a brain-stem or cerebellar syndrome were randomly assigned to receive weekly intramuscular graph injections of either interferon beta-1a or placebo. All patients had evidence on magnetic resonance imaging of prior subclinical demyelination in the brain. After three years of follow-up, significantly fewer patients in the interferon beta-1a group had progression to clinically definite multiple sclerosis (cumulative probability, 35 percent, vs. 50 percent in the placebo group).